Milestone Pharmaceuticals Inc. (NASDAQ:MIST) shares are tumbling on Friday after the company revealed a minor pushback in European approval for its lead drug.
• Milestone Pharmaceuticals stock is taking a hit today. Why is MIST stock falling?
European Decision Timeline Pushed
In January, the European Medicines Agency accepted the marketing application for etripamil in paroxysmal supraventricular tachycardia (PSVT), supported by the same global data package used for FDA approval in December 2025.
PSVT is a type of arrhythmia (irregular heartbeat) characterized by sudden, sporadic bursts of a rapid, regular heart rate (120–230 bpm) that start and stop abruptly.
The company expects a decision in the first half of 2027, compared to the first quarter of 2027, anticipated earlier.
Tachymist is the conditionally approved European brand name.
The company reported a …